Insights & Analysis

Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.

All News Activism M&A Podcasts Private Cos. Private Equity Restructuring Scoops & Exclusives SPACs

Page 22

Activism

Drinks With The Deal: Eduardo Gallardo of Gibson Dunn

By David Marcus
|
Published: December 16th, 2021
Eduardo Gallardo, co-chair of M&A and chair of the activist defense group at Gibson Dunn, discusses the universal proxy, the Williams case and more on this week's Drinks With The Deal podcast.
Podcasts

Drinks With The Deal: Gregory Varallo of Bernstein Litowitz

By David Marcus
|
Published: December 9th, 2021
The Delaware partner discusses the switch from representing companies to working with shareholders, Andy Bouchard's achievements as chancellor, his love of hunting, poker and the American University of Rome and more in this week's episode.
Activism

Drinks With The Deal: Willkie's Tariq Mundiya

By David Marcus
|
Published: December 2nd, 2021
Willkie head of litigation Tariq Mundiya discusses the Williams poison pill case from earlier this year as well as the CytoDyn decision and the evolution of Delaware's Caremark doctrine in this week's Drinks With The Deal podcast.
M&A

Drinks With The Deal: Squire Patton Boggs' James Barresi

By David Marcus
|
Published: November 18th, 2021
James Barresi, who heads the firm's financial services practice, explains how his time as an in-house lawyer at US Bancorp in the 1990s has shaped his approach to private practice and how he works with clients considering a deal.
Podcasts

Fresh Start: Professor Melissa Jacoby

By Stephanie Gleason
|
Published: October 25th, 2021
The University of North Carolina at Chapel Hill professor discusses finding the boundaries of bankruptcy in Purdue and more on the latest episode of Fresh Start.
M&A

Drinks With The Deal: Krishna Veeraraghavan of Paul Weiss

By David Marcus
|
Published: October 14th, 2021
M&A lawyer Krishna Veeraraghavan talked about healthcare dealmaking and the risks of excessive antitrust regulation of combinations between biotech and pharma companies in the Drinks With The Deal podcast.
 Company
Solutions
Contact The Deal
Tel:
+1 646 891 2135
International:
+44 (0) 20 7832 6500
Email:
[email protected]
© 2025 The Deal.

A With Intelligence company. All rights reserved. Privacy Policy, Cookies, Terms, Modern Slavery Act